BRAF and metastatic neoplasm: The vast majority of patients (89%) received at least one treatment for metastatic disease: first-line treatment was monochemotherapy ± a biologic agent (anti-EGFR monoclonal antibody or bevacizumab) in 9.4% of treated patients, doublet ± a biologic agent in 55.8%, triplet ± a biologic agent in 24.6%, immunotherapy in 7.3% and anti-BRAF treatment in 2.2%.